Stock exchanges & markets

Overview Watchlists

AbbVie says FDA approves Skyrizi for pediatric plaque psoriasis, psoriatic arthritis patients 6+

2 hours ago

(AWP Alliance News) - AbbVie secured FDA clearance to expand Skyrizi into pediatric psoriatic disease, covering children aged 6 and older with moderate-to-severe plaque psoriasis or active psoriatic arthritis. The label update adds a 55 mg prefilled syringe for weight-based dosing in patients weighing under 40 kg.

The drug is now the only IL-23 inhibitor cleared in the US for pediatric patients in this weight group with either condition.

https://www.prnewswire.com/news-releases/skyrizi-risankizumab-rzaa-now-…

Disclaimer: This news brief was created using generative artificial intelligence. AbbVie Inc. published the original content used to generate this news brief via PR Newswire on June 26, 2026, and is solely responsible for the information contained therein.

Lernen Sie unsere Angebote kennen

  • Create your own watchlist

    Watchlist

    Follow price trends and market data for your choice of shares, ETFs and other securities. All in one place.

    Register now

  • Mit diesen Aktien auf Dividenden setzen

    Attraktive Ausschüttungen

    Hierzulande gibt es viele Unternehmen, die zuverlässig Dividenden zahlen. Die grosse Übersicht zu Schweizer Aktien.

    Zur Dividenden-Übersicht